Elanco Animal Health (NYSE:ELAN) Lowered to Buy Rating by Wall Street Zen

Elanco Animal Health (NYSE:ELAN) was downgraded by equities research analysts at Wall Street Zen from a “strong-buy” rating to a “buy” rating in a research report issued on Sunday.

Several other brokerages have also weighed in on ELAN. KeyCorp raised their price objective on shares of Elanco Animal Health from $27.00 to $29.00 and gave the company an “overweight” rating in a research report on Wednesday, February 25th. Weiss Ratings lowered shares of Elanco Animal Health from a “sell (d+)” rating to a “sell (d)” rating in a research report on Monday, May 11th. Morgan Stanley raised their price objective on shares of Elanco Animal Health from $22.00 to $24.00 and gave the company an “equal weight” rating in a research report on Wednesday, February 25th. UBS Group reaffirmed a “buy” rating on shares of Elanco Animal Health in a research report on Tuesday, March 10th. Finally, JPMorgan Chase & Co. raised their price objective on shares of Elanco Animal Health from $28.00 to $30.00 and gave the company an “overweight” rating in a research report on Thursday, May 7th. One analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Elanco Animal Health has an average rating of “Moderate Buy” and a consensus target price of $28.20.

Elanco Animal Health Stock Performance

NYSE:ELAN opened at $21.77 on Friday. The firm has a market cap of $10.87 billion, a price-to-earnings ratio of -43.54, a price-to-earnings-growth ratio of 2.34 and a beta of 1.69. The company has a 50-day moving average of $23.02 and a 200-day moving average of $23.28. The company has a current ratio of 2.16, a quick ratio of 1.12 and a debt-to-equity ratio of 0.60. Elanco Animal Health has a twelve month low of $12.40 and a twelve month high of $27.72.

Elanco Animal Health (NYSE:ELAN) last issued its quarterly earnings data on Wednesday, May 6th. The company reported $0.40 earnings per share for the quarter, beating the consensus estimate of $0.34 by $0.06. The firm had revenue of $1.37 billion for the quarter, compared to analyst estimates of $1.28 billion. Elanco Animal Health had a negative net margin of 4.95% and a positive return on equity of 7.42%. The company’s revenue for the quarter was up 14.9% on a year-over-year basis. During the same quarter last year, the firm earned $0.37 earnings per share. Elanco Animal Health has set its Q2 2026 guidance at 0.250-0.285 EPS and its FY 2026 guidance at 1.030-1.090 EPS. Analysts forecast that Elanco Animal Health will post 1.11 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, insider Rajeev A. Modi purchased 4,911 shares of the company’s stock in a transaction dated Friday, May 15th. The shares were bought at an average price of $20.35 per share, with a total value of $99,938.85. Following the completion of the transaction, the insider directly owned 160,812 shares in the company, valued at $3,272,524.20. This trade represents a 3.15% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Jeffrey N. Simmons purchased 4,971 shares of the company’s stock in a transaction dated Friday, May 15th. The stock was purchased at an average cost of $20.09 per share, for a total transaction of $99,867.39. Following the transaction, the chief executive officer owned 171,971 shares of the company’s stock, valued at approximately $3,454,897.39. This trade represents a 2.98% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Company insiders own 1.14% of the company’s stock.

Hedge Funds Weigh In On Elanco Animal Health

A number of institutional investors have recently modified their holdings of the company. Bank of America Corp DE raised its position in shares of Elanco Animal Health by 38.0% in the first quarter. Bank of America Corp DE now owns 3,358,215 shares of the company’s stock valued at $80,362,000 after purchasing an additional 924,032 shares during the period. Janus Henderson Group PLC grew its stake in shares of Elanco Animal Health by 4.9% in the first quarter. Janus Henderson Group PLC now owns 226,000 shares of the company’s stock worth $5,413,000 after acquiring an additional 10,600 shares during the last quarter. Arkadios Wealth Advisors grew its stake in shares of Elanco Animal Health by 20.0% in the first quarter. Arkadios Wealth Advisors now owns 63,457 shares of the company’s stock worth $1,519,000 after acquiring an additional 10,589 shares during the last quarter. Amundi grew its stake in shares of Elanco Animal Health by 101.9% in the first quarter. Amundi now owns 98,313 shares of the company’s stock worth $2,353,000 after acquiring an additional 49,608 shares during the last quarter. Finally, EverSource Wealth Advisors LLC grew its stake in shares of Elanco Animal Health by 51.9% in the first quarter. EverSource Wealth Advisors LLC now owns 9,415 shares of the company’s stock worth $225,000 after acquiring an additional 3,215 shares during the last quarter. Institutional investors own 97.48% of the company’s stock.

Elanco Animal Health Company Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.